Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls
Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters
Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs
Handwipe Disclosing Method for Detecting the Presence of Lead
Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces
Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology
The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine.
Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies
This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1.
Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization
This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies.